Author | Eric Jonasch, MD

Articles

Eric Jonasch, MD, on Next Steps in MK-6482 in VHL Disease–Associated RCC

June 02, 2020

The MD Anderson Cancer Center expert discussed next steps for those with von Hippel-Lindau disease–associated renal cell carcinoma being treated with the HIF-2a Inhibitor.

Eric Jonasch, MD, Discusses Use of MK-6482 in VHL Disease–Associated Kidney Cancer

May 30, 2020

The HIF-2a Inhibitor, MK-6482, induced clinical responses among patients with von Hippel-Lindau disease–associated renal cell carcinoma.